Drug interactions in the elderly;Arzneimittelinteraktionen im alter

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 16, 2004, Pages 895-900

  Bramlage, P ^a   Siepmann, M ^a   Kirch, W ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMIODARONE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CODEINE; CYCLOSPORIN; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROMYCIN; INDAPAMIDE; KETOCONAZOLE; MORPHINE; OPIATE; PARACETAMOL; POTASSIUM; PROPAFENONE; QUINIDINE; RIFAMPICIN; SIMVASTATIN; SODIUM; SPIRONOLACTONE; TACROLIMUS; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNINDEXED DRUG; VERAPAMIL;

AGED; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ELIMINATION; DRUG METABOLISM; ELDERLY CARE; GASTROINTESTINAL TRACT; HEART DISEASE; HEPATOBILIARY SYSTEM; HUMAN; HYDROLYSIS; HYPERKALEMIA; HYPERTENSION; LIVER FUNCTION; MONOTHERAPY; OXIDATION; REDUCTION; RENAL SYSTEM PARAMETERS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; URINARY EXCRETION;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; DRUG INTERACTIONS; HUMANS; RISK FACTORS;

EID: 1942436701     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-823036     Document Type: Review

References (40)

1. K/DOQI clinical practice guidelines for chronic kidney disease, evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39: S1-246
2. Beers MH, Ouslander JG, Fingold SF et al. Inappropriate medication prescribing in skilled-nursing facilities. Ann Intern Med 1992; 117: 684-689
3. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med 1991; 151: 1825-1832
4. Farmer JA. Learning from the cerivastatin experience. Lancet 2001; 358: 1383-1385
5. Frölich JC. Besonderheiten der Pharmakotherapie in der Geriatrie. Heidelberg: Springer, In: Frölich JC, Kirch W, Hrsg. Praktische Arzneitherapie. 3. Auflage. 2003: 95-109
6. Fromm MF. Unerwartet hohe Plasmaspiegel von Arzneimitteln. Blockierter Transporter kann die Ursache sein. MMW Fortschr Med 2001; 143: 36-37
7. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 552-557
8. Guazzi M, Brambilla R, Reina G, Tumminello G, Guazzi MD. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. Arch Intern Med 2003; 163: 1574-1579
9. Ha HR, Candinas R, Stieger B, Meyer UA, Follath F. Interaction between amiodarone and lidocaine. J Cardiovasc Pharmacol 1996; 28: 533-539
10. Harder S, Thürmann P. Clinically important drug interactions with anticoagulants: An update. Clin Pharmacokinet 1996; 30: 416-444
11. Heft MW, Mariotti AJ. Geriatric pharmacology. Dent Clin North Am 2002; 46: 869-885
12. Herrlinger C, Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 2001; 15: 897-918
13. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-3478
14. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54: 159-161
15. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652-1658
16. Kelly JG, McGarry K, O'Malley K, O'Brien ET. Bioavailability of labetalol increases with age. Br J Clin Pharmacol 1982; 14: 304-305
17. Kirch W. Arzneimittelwechselwirkungen. Berlin: Springer, In: Fröhlich JC, Kirch W, Hrsg. Praktische Arzneitherapie. 3. Auflage. 2003: 128-132
18. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33: 278-285
19. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002; 36: 1331-1336
20. Mullins ME, Horowitz BZ, Linden DH, Smith GW, Norton RL, Stump J. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 1998; 280: 157-158
21. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-850
22. Nink K, Schröder H. Arzneimittelverordnungen nach Alter und Geschlecht. Berlin: Springer, In: Schwabe U, Paffrath D, Hrsg. Arzneimittelreport 2003. 2004: 959-971
23. Patterson TF, Peters J, Levine SM et al. Systemic availability of itraconazole in lung transplantation. Antimicrob Agents Chemother 1996; 40: 2217-2220
24. Phister JE, Jue SG, Cusack BJ. Problems in the use of anticancer drugs in the elderly. Drugs 1989; 37: 551-565
25. Pittrow D, Krappweis J, Kirch W. Use of drugs in residents of homes for the elderly and nursing homes in comparison with patients in ambulatory care or without need of care. Dtsch Med Wochenschr 2002; 127: 1995-2000
26. Pittrow D, Krappweiss J, Rentsch A et al. Pattern of prescriptions issued by nursing home-based physicians versus office-based physicians for frail elderly patients in German nursing homes. Pharmacoepidemiol Drug Safety 2003; 12: 1-5
27. Podrazik P〈 /FN〉M, Schwartz JB. Cardiovascular pharmacology of aging. Cardiol Clin 1999; 17: 17-34
28. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998; 351: 1929-1930
29. Schwabe U, Paffrath D. Arzneimittelreport 2003. Berlin: Springer, 2004
30. Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994; 55: 509-517
31. Seymour RM, Routledge PA. Important drug-drug interactions in the elderly. Drugs Aging 1998; 12: 485-494
32. Sloan RW. Drug interactions. Am Fam Physician 1983; 27: 229-238
33. SoRelle R. Withdrawal of Posicor from market. Circulation 1998; 98: 831-832
34. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19: 299-320
35. Statistisches Jahrbuch, Statistisches-Bundesamt, 2001
36. Tamai IY, Strome LS, Marshall CE, Mooradian AD. Analysis of drug-drug interactions among nursing home residents. Am J Hosp Pharm 1989; 46: 1567-1569
37. Tamblyn RM, McLeod PJ, Abrahamowicz M, Laprise R. Do too many cooks spoil the broth? Multiple physician involvement in medical management of elderly patients and potentially inappropriate drug combinations. CMAJ 1996; 154: 1177-1184
38. Tateishi T, Fujimura A, Shiga T, Ohashi K, Ebihara A. Influence of aging on the oxidative and conjugative metabolism of propranolol. Int J Clin Pharmacol Res 1995; 15: 95-101
39. Williams CM. Using medications appropriately in older adults. Am Fam Physician 2002; 66: 1917-1924
40. Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ 2003; 327: 147-149